ArticleJournal of injury & violence research2015
Acute kidney injury.
Article in Journal of injury & violence research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Endovascular repair for acute traumatic transection of the descending thoracic aorta: experience of a single centre with a 12-years follow up.Journal of cardiothoracic surgery · 2015Trial
- Tirzepatide-associated interstitial kidney injury.JCEM case reports · 2026Article
- Assessment and Management of Electrical Injuries in Adults in the Emergency Department.Cureus · 2026Review
- Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.Cancer chemotherapy and pharmacology · 2026Article
- Central Diabetes Insipidus in Suprasellar Germ Cell Tumor Paradoxically Presenting With Oliguria.Clinical case reports · 2026Article
- Engineered Neuromedin U Promotes Type 2 Innate Immunity and Renoprotection in Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025Article
- Comprehensive Analysis of RNA Methylation-Regulated Gene Signature and Immune Infiltration in Ischemia/Reperfusion-Induced Acute Kidney Injury.Kidney & blood pressure research · 2025Article
- miRNA and mRNA Signatures in Human Acute Kidney Injury Tissue.The American journal of pathology · 2025Article
- The Kidney Precision Medicine Project and Single-Cell Biology of the Injured Proximal Tubule.The American journal of pathology · 2025Review
- An Insidious Case of Rapidly Progressive Glomerulonephritis Secondary to Pauci-Immune Crescentic Glomerulonephritis.Cureus · 2024Article
- Beta-lactam-associated hypokalemia.The Journal of international medical research · 2024Review
- Subcutaneous injection of adipose stromal cell-secretome improves renal function and reduces inflammation in established acute kidney injury.Stem cell research & therapy · 2024Article
- The Role of Oxidative Stress in Kidney Injury.Antioxidants (Basel, Switzerland) · 2023Review
- An Incidental Finding of a Glucagon-Like Peptide 1 (GLP-1)-Induced Acute Kidney Injury: A Case Report.Cureus · 2023Article
- Vitamin A and retinoid signaling in the kidneys.Pharmacology & therapeutics · 2023Review
- Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Oxypurinol protects renal ischemia/reperfusion injuryFrontiers in medicine · 2023Article
- The Nephrotoxicity of Drugs Used in Causal Oncological Therapies.Current oncology (Toronto, Ont.) · 2022Review
- Association Between Iron Metabolism and Acute Kidney Injury in Critically Ill Patients With Diabetes.Frontiers in endocrinology · 2022Article
- The Delivery of the Recombinant Protein Cocktail Identified by Stem Cell-Derived Secretome Analysis Accelerates Kidney Repair After Renal Ischemia-Reperfusion Injury.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury is a frequent and serious complication in hospitalized patients. Mortality rates have not substantially been decreased during the last 20 years. In most patients AKI results from transient renal hypoperfusion or ischemia. The consequences include tubular cell dysfunction/damage, inflammation of the organ, and post-ischemic microvasculopathy. The two latter events perpetuate kidney damage in AKI. Clinical manifestations result from diminished excretion of water, electrolytes, and endogenous / exogenous waste products. Patients are endangered by cardiovascular complications such as hypertension, heart failure, and arrhythmia. In addition, the whole organism may be affected by systemic toxification (uremia). The diagnostic approach in AKI involves several steps with renal biopsy inevitable in some patients. The current therapy focuses on preventing further kidney damage and on treatment of complications. Different pharmacological strategies have failed to significantly improve prognosis in AKI. If dialysis treatment becomes mandatory, intermittent and continuous renal replacement therapies are equally effective. Thus, new therapies are urgently needed in order to reduce short- and long-term outcome in AKI. In this respect, stem cell-based regimens may offer promising perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.